Industry Outlook: Scaling Medical Psychedelic Care & Reimbursement

This interview with Dr. Brian Barnett delves into the future of scaling medical psychedelic treatments, addressing psychiatrist perceptions, the role of ketamine, and critical challenges like reimbursement models (RVUs). While not focused on immediate legislation, it offers valuable insight into the evolving regulatory and financial frameworks that will shape the accessibility and delivery of approved psychedelic therapies.

An interview with Dr. Brian Barnett, a leading psychiatrist and clinical trial investigator, provides insights into the future of scaling psychedelic care. The discussion covers critical aspects such as reimbursement strategies (RVUs), real-world delivery settings, and psychiatrists' evolving perceptions of treatments like ketamine, LSD, and psilocybin. This content highlights the systemic challenges and opportunities involved in making approved psychedelic therapies widely accessible, offering a glimpse into the evolving medical landscape and its potential influence on broader market regulation.

Sentinel Insight